Malignant pleural disease

Malignant pleural disease usually heralds a poor prognosis, whether it represents a primary pleural malignancy or metastatic involvement

Clinical presentation is variable. Patients may be asymptomatic or have pleuritic pain. If associated with a sizeable pleural effusion, then respiratory compromise may be evident. If the tumour is from the chest wall, then musculoskeletal pain or even a palpable mass may be present.

The pleura can be involved by malignancy by three main mechanisms:

  1. direct extension from adjacent tumour, e.g. bronchogenic carcinoma
  2. primary tumour, e.g. mesothelioma, primary pleural lymphoma
  3. pleural metastases

In each of these the manifestation can be either solid disease or a malignant pleural effusion, or a combination of both. The relative aetiology is 1,6

Conventional imaging is in general highly specific for the diagnosis of pleural malignancy but unfortunately lacks sensitivity 3

Plain films in the setting of malignant pleural effusion are insensitive at distinguishing it from a benign effusion. See malignant vs benign pleural effusion

In cases where multiple nodular regions or pleural thickening are present the diagnosis may be evident, especially if the primary tumour or other metastatic deposits are visible.

CT is the work-horse of pleural imaging, able to achieve specificities of close to 100% 3. The portal-venous phase is optimal for demonstrating pleural enhancement, rather than arterial phase imaging used routine thoracic CT. A number of features are recognised, including 1,3:

In many cases the primary malignancy will be visible (e.g. breast cancer, bronchogenic cancer) and/or evidence of pulmonary or bony metastases will be visible. 

FDG-PET is far more sensitive than conventional imaging in diagnosing malignant pleural disease and distinguishing them from benign processes 3. Hypermetabolism can be seen in either the pleura or pleural effusion. Although both benign and malignant processes, benign processes rarely increase the SUV over 2.0 3

MRI findings of high signal intensity on T2 in relation to intercostal muscles and/or contrast-enhanced on T1 images together with CT morphology has a a 100% and a specificity of 93% in the detection of pleural malignancy 5.

Both treatment and prognosis are dependent on the underlying type of malignancy. In the case of primary malignancies of the pleura (e.g. mesothelioma) resection may be a possibility in highly selected cases.

Thoracentesis of malignant pleural effusions has limited effect with reaccumulation occurring, on average, at four days. 

In general, and certainly in the case of diffuse pleural metastatic disease, systemic therapies or radiotherapy are the only options. These are discussed separately as part of articles pertaining to individual malignancies:

Differential diagnosis depends on the predominant form the pleural disease takes:

Share article

Article information

rID: 8730
Systems: Chest, Oncology
Section: Pathology
Synonyms or Alternate Spellings:
  • Malignant pleural thickening
  • Pleural malignancies
  • Pleural malignancy
  • Malignancies of the pleura
  • Malignant pleural effusion
  • Malignancy of the pleura
  • Malignant pleural effusions

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    Thymoma
    Case 1: thymoma - invasive
    Drag here to reorder.
  • Drag
    Case 2: mesothelioma
    Drag here to reorder.
  • Drag
    Pleural metastase...
    Case 3: pleural metastases from thyroid cancer
    Drag here to reorder.
  • Drag
    Case 4: pleural carcinomatosis from breast cancer
    Drag here to reorder.
  • Drag
    Case 5: non-hodgkin lymphoma
    Drag here to reorder.
  • Drag
    Case 6: malignant melanoma
    Drag here to reorder.
  • Drag
    Case 7: from unknown primary
    Drag here to reorder.
  • Drag
    Case 8: malignant pleural effusion
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.